Ethaselen (BBSKE) is a novel, oral and potent organoselenium-based inhibitor of thioredoxin reductase (TrxR) with potential anticancer activity. It inhibits wild-type human TrxR1 and rat TrxR1 with IC50 values of 0.5 and 0.35 μM, respectively. Ethaselen is under investigation in clinical trials in China for cancer (NSCLC) treatment.

纯度：≥98%

CAS：217798-39-5